Term
Chlor-promazine (Thorazine)
-category
-mode of action
-effect
-side effects |
|
Definition
-Phenothiazine
--Dopamine (D2) antagonist
-Antipsychotic
-TCA side effects (dirty drug) |
|
|
Term
Pro-Methazine (Phenergan)
-category
-mode of action
-effect |
|
Definition
-phenothiazine
-anti-histamine, blocks M, blocks H1 in brain
-treats pruitis (itching); motion sickness; and acts as a sedative (TCA like) |
|
|
Term
Pro-Chlor-Perazine (Compazine)
-category
-mode of action
-effect |
|
Definition
-Phenothiazine
-TCA-like, D2 blocker
-for drug induced nausea and migraine (but better to use sertrons aka 5-HT3 blockers) |
|
|
Term
Flu-Phenazine (Permitil) and Tri-Fluo-Perazine (Stelazine)
-category
-mode of action
-effect |
|
Definition
-Phenothiazines
-TCA like (D2 blocker)
-long-term antipsychotic for non-compliant patients
|
|
|
Term
| 4 categories of neuroleptic (antipsychotic) drugs |
|
Definition
-Phenothiazines (TCA like)
-Butyrophenones
-Thioxanthenes
-Benzamides
|
|
|
Term
Haloperidol
-category
-mode of action
-effect
-side effects |
|
Definition
-Butryophenones
-More selective D2 blocker without TCA side effects
-antipsychotic
-D2 blocker related: extrapyramidal symptoms (Parkinson-like, motor side effects), the worst being tardive dyskinesia which is irreversible
|
|
|
Term
Pseudo Parkinsonism drugs
-mode of action
-four examples |
|
Definition
-decrease in dopamine leads to increase in Ach, so these drugs counter that with atropine, anti-cholinergenic effects
-Benztropine (esp for dystonia), Trihexyphenidyl (also anti M), Diphenhydramine (Benadryl, also antihistamine), Amantadine |
|
|
Term
Clozapine (Di-Benzo-diazepine)
-Category
-Mode of action
-Effects
-Side effects
-Metabolism |
|
Definition
-Atypical neuroleptic (all P450 metabolized)
-D4 and 5-HT2 antagonists (high affinity) and low affinity D2 antagonist.
-Antipsychotic (effective against negative symptoms like withdrawal...as opposed to positive symptoms like hearing voices)
-TCA-like: sedation (H2 blocker), orthostasis/reflex tackycardia (β1 blocker), QT prolongation (K+ channel blocker) hypersalivation (rare for a TCA), hyperthermia (anticholinergic effect in periphery) and seizures (due to hyperthermia), but less EPS (extra pyramidal, Parkinson-like symptoms like dystonia etc.); Agranulocytosis: supressed red blood cell production needing blood monitoring; weight gain (10 by 10 = 10 lbs by 10 weeks)
-P450 1A2 like Xanthines |
|
|
Term
Olanzapine
-category
-effects
-side effects
-metabolism |
|
Definition
-Atypical neuroleptic
-D4 and 5-HT2 antagonists (high affinity) and low affinity D2 antagonist.
-Antipsychotic (effective against negative symptoms like withdrawal...as opposed to positive symptoms like hearing voices)...NO Agranulocytosis!
-TCA-like: sedation (H2 blocker), orthostasis/reflex tackycardia (β1 blocker), QT prolongation (K+ channel blocker) hypersalivation (rare for a TCA), hyperthermia (anticholinergic effect in periphery) and seizures (due to hyperthermia), but less EPS (extra pyramidal, Parkinson-like symptoms like dystonia etc.); ; weight gain (10 by 10 = 10 lbs by 10 weeks)
-P450 1A2 like Xanthines |
|
|
Term
Ziprasidone (Geodon)
-Mode of action
-Effect
-Side effect |
|
Definition
-5-HT2 antagonist and NASRI (SNRI) reuptake inhibitor (little effect on D2 receptor)
-Anti-depressant
-QT prolongation (K+ channel blocker) |
|
|
Term
Quetiapine
-Category
-Effect
-Side effects |
|
Definition
-Atypical neuroleptic
-anti-psychotic
-Sedating, cataract development, hypothyroidism |
|
|
Term
Aripiprazole (Abilify)
-Mode of action
-Effect
-Side effect?
-Metabolism |
|
Definition
-5HT2 antagonist; 5HT1A partial agonist (Buspirone-like); D2 partial agonist
-antipsychotic
-less weight gain
-P450 2D6 & 3A4 |
|
|
Term
Parkinson's therapy
-3 part way of increasing dopamine |
|
Definition
-Carbidopa (Decarboxylase Inhibitor that stays in blood, allowing Levodopa to pass blood brain barrier before being converted to dopamine which cannot pass barrier)
-Levadopa
-Entacapone (COMT ie methyl transferase inhibitor, which stops Levadopa from being metabolized in the brain)
-Stalevo (combines all three)
|
|
|
Term
Selegeline (Antiparkin)
-Mode of action
-Effect |
|
Definition
-MAO-B (metabolizes dopamine) inhibitor
-treats Parkinson disease by increasing dopamine levels |
|
|
Term
Bromcriptine and Pergolide
-Category
-Mode of action
-Effect
-Side effects |
|
Definition
-Ergotamine derivatives
-Dopamine receptor agonists
-psychosis, nausea and vomitting (D2 agonist in CRTZ), orthostatic hypotension (usually α1 blocker, but also D2 agonist in periphery causes vasodilation), fibrosis (pulmonary and retroperitoneal), vasospasm and GI ulceration
|
|
|
Term
Pramipexole and Ropinrole
-Category
-Mode of action
-effect
-Side effects |
|
Definition
-Non-ergotamine derivatives
-Dopamine receptor agonists
-Anti-Parkinson with NO fibrosis or vasospasms
-Same as erotamine derivatives (psychosis, N&V, orthostatic hypotension, GI ulceration) with NO fibrosis or vasospasms |
|
|
